Clinical Trials Browser

Phase 1/2 × Transurethral Resection of Bladder × 30 days × Clear all

NCT07579195 2026-05-14

Consolidative Therapy After EV + Pembrolizumab in Muscle Invasive Bladder Cancer, REINFORCE Trial

Phase 1/2 Not yet recruiting

Urinary Bladder Neoplasms